NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

BIIB

Biogen Inc

Jul 14 • 04:00PM ET

133.11

Dollar change -1.10
Percentage change -0.82	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO QQQ SPY IVV VTV COWZ RSP XLV

Index	NDX, S&P 500	P/E	13.15	EPS (ttm)	10.13	Insider Own	0.19%	Shs Outstand	146.50M	Perf Week	2.29%
Market Cap	19.50B	Forward P/E	8.65	EPS next Y	15.38	Insider Trans	-3.91%	Shs Float	146.25M	Perf Month	0.04%
Enterprise Value	23.53B	PEG	-	EPS next Q	4.01	Inst Own	89.89%	Short Float	2.74%	Perf Quarter	17.40%
Income	1.48B	P/S	2.07	EPS this Y	-10.51%	Inst Trans	-0.62%	Short Ratio	2.70	Perf Half Y	-11.70%
Sales	9.40B	P/B	1.15	EPS next Y	4.35%	ROA	5.42%	Short Interest	4.00M	Perf YTD	-12.95%
Book/sh	115.90	P/C	7.51	EPS next 5Y	-0.84%	ROE	9.19%	52W High	238.00 -44.07%	Perf Year	-42.81%
Cash/sh	17.73	P/FCF	8.00	EPS past 3/5Y	2.46% -18.66%	ROIC	6.77%	52W Low	110.04 20.97%	Perf 3Y	-38.37%
Dividend Est.	-	EV/EBITDA	8.18	Sales past 3/5Y	-3.78% -6.13%	Gross Margin	66.54%	Volatility	3.02% 2.82%	Perf 5Y	-49.79%
Dividend TTM	-	EV/Sales	2.50	EPS Y/Y TTM	26.10%	Oper. Margin	22.62%	ATR (14)	3.77	Perf 10Y	-64.35%
Dividend Ex-Date	-	Quick Ratio	1.01	Sales Y/Y TTM	1.25%	Profit Margin	15.73%	RSI (14)	55.72	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	1.44	EPS Q/Q	-39.16%	SMA20	2.58%	Beta	0.13	Target Price	171.30
Payout	0.00%	Debt/Eq	0.39	Sales Q/Q	6.17%	SMA50	3.99%	Rel Volume	0.46	Prev Close	134.21
Employees	7605	LT Debt/Eq	0.29	Earnings	May 01 BMO	SMA200	-9.01%	Avg Volume	1.48M	Price	133.11
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.16% 8.81%	Trades		Volume	694,370	Change	-0.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327

Show Previous Ratings

Today 04:00AM	Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors (GlobeNewswire)
Jul-14-25 04:01AM	Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 \| Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments (GlobeNewswire)
Jul-11-25 07:34PM	Analyst Report: Biogen Inc. (Morningstar Research)
Jul-10-25 11:14AM	RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT (Insider Monkey)
07:00AM	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (Business Wire)
07:00AM	Loading…
07:00AM	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (GlobeNewswire)
Jul-08-25 09:59AM	DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review (Zacks)
Jul-02-25 07:11PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Jul-01-25 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks)
12:03AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Jun-30-25 08:42AM	AbbVie to buy Capstan for up to $2.1 billion in immunology push (Reuters)
08:18AM	RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimers market (Investing.com)
07:30AM	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy (GlobeNewswire)
Jun-28-25 10:05AM	Biogen highlights promising results for higher-dose nusinersen in SMA trials (TipRanks)
04:16AM	Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results (Insider Monkey)
10:00AM	Loading…
Jun-27-25 10:00AM	New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA (GlobeNewswire)
Jun-26-25 03:46AM	5 Revealing Analyst Questions From Biogen's Q1 Earnings Call (StockStory)
Jun-25-25 04:46PM	Biogen's Friedreich's Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations (Insider Monkey)
04:19PM	Can Biogen Save Even More Kids With This New Drug? (Investor's Business Daily)
11:41AM	Biogens Spinraza successor advances to Phase III (Clinical Trials Arena)
10:47AM	Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics (GlobeNewswire)
07:33AM	Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? (Investor's Business Daily)
07:31AM	Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results (Business Wire)
07:30AM	Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results (GlobeNewswire)
Jun-24-25 03:36AM	Biogen scores Cannes Festival win with dark humored campaign (Pharma Voice)
Jun-23-25 01:36AM	Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia. (Insider Monkey)
Jun-19-25 07:38AM	Biogen starts dosing in Phase III trial of Friedreich ataxia therapy (Clinical Trials Arena)
Jun-18-25 11:08AM	21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity (Business Wire)
09:45AM	H.C. Wainwright sees potential competition for Sage from Biogen (TipRanks)
07:30AM	Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia (GlobeNewswire)
02:36PM	Loading…
Jun-17-25 02:36PM	SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal (Zacks)
11:20AM	Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With 'Fit for Growth' Plan (Insider Monkey)
08:00AM	Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer (GlobeNewswire)
Jun-16-25 04:21PM	Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics (Investor's Business Daily)
11:43AM	Supernus makes depression drug play with $795m Sage buyout (Pharmaceutical Technology)
09:14AM	Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million (Investor's Business Daily)
08:17AM	Sage, following Setbacks, to sell to Supernus for $561M (BioPharma Dive)
Jun-15-25 05:38AM	Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 (Insider Monkey)
Jun-12-25 01:00AM	Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity (GlobeNewswire)
Jun-05-25 11:30AM	Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report? (Zacks)
Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
May-29-25 11:34PM	Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks (StockStory)
May-28-25 05:24AM	Biogen and City Therapeutics to develop RNAi therapy (Pharmaceutical Technology)
May-27-25 07:58PM	Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal (Insider Monkey)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:30AM	Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies (GlobeNewswire)
May-22-25 10:14AM	Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout (Zacks)
May-20-25 08:58AM	Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study (Zacks)
May-13-25 04:58PM	Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom (Insider Monkey)
May-12-25 08:00AM	How To Invest: Using Shorter-Term Moving Averages To Trade Stocks (Investor's Business Daily) +5.27%
May-08-25 11:51PM	Q1 2025 Royalty Pharma PLC Earnings Call (Thomson Reuters StreetEvents)
May-07-25 01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-06-25 12:32AM	2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore (StockStory)
May-05-25 02:19PM	Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (Seeking Alpha)
May-04-25 12:00PM	4 Stocks to Buy for a Potential Summer Panic (InvestorPlace)
May-02-25 03:05AM	Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ... (GuruFocus.com)
12:43AM	Q1 2025 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 02:07PM	Biogens Q1 revenue soars past estimates as rare disease pivot pays off (Pharmaceutical Technology)
12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
11:38AM	Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:42AM	Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View (Zacks)
09:30AM	Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
06:48AM	Biogen's results beat estimates on strength in rare disease drugs (Reuters)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:15AM	Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
08:05AM	Q1 2025 SAGE Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-29-25 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
06:32AM	The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron (Zacks)
Apr-28-25 12:08PM	Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? (Zacks)
Apr-25-25 09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
Apr-24-25 10:01AM	Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline (Zacks)
06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
04:54AM	Biogens Friedreichs ataxia treatment authorised in UK (Pharmaceutical Technology)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
09:45AM	EC authorises Eisai and Biogens lecanemab for Alzheimers (Pharmaceutical Technology)
09:13AM	European regulators OK Alzheimer's treatment Leqembi after initial doubts (Associated Press Finance)
Apr-15-25 07:00PM	Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union (GlobeNewswire)
Apr-11-25 06:56AM	Alzheons Alzheimers pill fails in Phase III trial (Clinical Trials Arena)
Apr-10-25 12:01PM	Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. (Investor's Business Daily) -5.90%
09:53AM	Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock? (Zacks)
Apr-09-25 05:11PM	Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story (Seeking Alpha) +5.65%
05:34AM	Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag (Seeking Alpha)
Apr-04-25 07:49PM	Analyst Report: Biogen Inc. (Morningstar Research) -5.91%
11:49AM	Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell? (Investor's Business Daily)
Apr-03-25 10:48AM	BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag (Zacks)
06:33AM	FDA grants fast track status to Biogen's BIIB080 for Alzheimer's (Pharmaceutical Business Review)
Apr-02-25 10:01AM	Organon acquires Actemra biosimilars US rights from Biogen (Pharmaceutical Technology)
07:30AM	Biogens Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimers Disease (GlobeNewswire)
Apr-01-25 07:30AM	Organon Acquires TOFIDENCE (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA (tocilizumab) Injection, for Intravenous Infusion in the U.S. (Business Wire)
Mar-31-25 10:00AM	Is the Future Bleak for SAVA Stock Following Another Setback? (Zacks)
Mar-28-25 08:13AM	Lilly hits same Alzheimers roadblock in Europe as Eisai, Biogen (BioPharma Dive)
12:55AM	ClearBridge Growth ESG Portfolios Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 04:14PM	Biogen: Balancing Risks And Opportunities (SeekingAlpha)
09:15AM	Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 (Motley Fool)
08:31AM	IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi (Zacks)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM

Open in Screener

VSTM

Verastem Inc

Jul 14 • 04:00PM ET

4.96

Dollar change +0.28
Percentage change 5.87	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD AMGN MRK PFE BMY REGN VRTX INCY LUMO SRPT

| Held by: VTI XBI IWM VXF VTWO FESM VFMO IWO IWN IWC

Index	RUT	P/E	-	EPS (ttm)	-3.19	Insider Own	11.00%	Shs Outstand	51.49M	Perf Week	5.76%
Market Cap	272.55M	Forward P/E	-	EPS next Y	-2.21	Insider Trans	-1.56%	Shs Float	48.90M	Perf Month	-16.92%
Enterprise Value	231.78M	PEG	-	EPS next Q	-0.73	Inst Own	69.49%	Short Float	32.21%	Perf Quarter	9.73%
Income	-148.88M	P/S	27.26	EPS this Y	18.52%	Inst Trans	16.25%	Short Ratio	7.20	Perf Half Y	-15.93%
Sales	10.00M	P/B	-	EPS next Y	26.02%	ROA	-116.66%	Short Interest	15.75M	Perf YTD	-4.06%
Book/sh	-0.63	P/C	2.32	EPS next 5Y	27.15%	ROE	-2159.50%	52W High	9.10 -45.49%	Perf Year	81.68%
Cash/sh	2.14	P/FCF	-	EPS past 3/5Y	9.28% 31.36%	ROIC	-360.19%	52W Low	2.10 136.19%	Perf 3Y	-62.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	154.59% -10.54%	Gross Margin	99.70%	Volatility	4.87% 6.79%	Perf 5Y	-72.44%
Dividend TTM	-	EV/Sales	23.18	EPS Y/Y TTM	27.49%	Oper. Margin	-1310.71%	ATR (14)	0.38	Perf 10Y	-94.49%
Dividend Ex-Date	-	Quick Ratio	3.50	Sales Y/Y TTM	-	Profit Margin	-1488.76%	RSI (14)	45.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.50	EPS Q/Q	23.79%	SMA20	4.26%	Beta	0.80	Target Price	15.25
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-19.25%	Rel Volume	0.80	Prev Close	4.68
Employees	78	LT Debt/Eq	-	Earnings	May 13 AMC	SMA200	-6.69%	Avg Volume	2.19M	Price	4.96
IPO	Jan 27, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-37.14% 60.00%	Trades		Volume	1,729,901	Change	5.87%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform

Show Previous Ratings

Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
08:41AM	Loading…
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%
May-28-25 10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks) -10.68%
07:30AM	Verastem Oncology to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-25 05:15PM	Verastem announces positive Phase 1/2 safety and efficacy results in PDAC (TipRanks) +11.10%
May-22-25 05:01PM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
May-13-25 04:50PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:34PM	Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
11:55AM	Loading…
May-09-25 11:55AM	FDA grants accelerated approval to avutometinib, defactinib combination (TipRanks)
May-08-25 02:47PM	FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer (Benzinga)
01:17PM	FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
May-01-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-25 09:00AM	Verastem Oncology Announces $75 million Private Placement (Business Wire)
Apr-23-25 04:05PM	Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors (Business Wire) +5.34%
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks) +13.37%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha) -14.39%
Apr-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:55AM	Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade (Zacks) +5.16%
Mar-25-25 04:35PM	Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 05:15PM	Verastem files to sell 1.42M shares of common stock by selling shareholders (SeekingAlpha)
04:17PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
07:33AM	Loading…
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%
Jan-14-25 07:30AM	Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China (Business Wire) -5.62%
Jan-13-25 07:30AM	Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 (Business Wire) -6.81%
Jan-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.79%
Dec-31-24 10:33AM	Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application (GuruFocus.com) +40.87%
Dec-30-24 04:30PM	Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-20-24 07:00AM	Applied Therapeutics Appoints John H. Johnson as Executive Chairman (GlobeNewswire) -5.63%
Dec-18-24 07:30AM	Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire) -7.39%
Nov-26-24 07:00AM	Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-24 05:00PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -6.98%
04:05PM	Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-01-24 12:02PM	Verastem Oncology submits NDA for ovarian cancer treatment (Pharmaceutical Technology)
Oct-31-24 04:01PM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
07:30AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Oct-17-24 01:00AM	Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting (Business Wire) -20.12%
Oct-09-24 06:00AM	Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting (Business Wire)
Oct-07-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-10-24 04:05PM	Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference (Business Wire) +8.76%
07:30AM	Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting (Business Wire)
Sep-03-24 07:30AM	Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 (Business Wire)
Aug-08-24 06:18PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-29-24 04:01PM	Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer (Business Wire) -7.43%
Jul-23-24 11:20PM	Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire) -17.55%
04:05PM	Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire)
Jul-15-24 11:42AM	Verastem (VSTM) Begins Dosing in Solid Tumors Study in China (Zacks)
04:52AM	Verastem announces dosing of first patient in trial of KRAS G12D inhibitor (Clinical Trials Arena)
Jul-12-24 07:30AM	Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics (Business Wire) +12.75%
Jul-08-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-24 07:30AM	Verastem Oncology Announces Addition to Russell 3000 and Russell Microcap Indexes (Business Wire) +9.06%
Jun-19-24 07:00AM	GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation (PR Newswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-06-24 06:45AM	7 F-Rated Stocks to Avoid at All Costs in June (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-24-24 12:28PM	Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data (Zacks) -66.17%
11:43AM	Is the Stock Market Open on Memorial Day 2024? (InvestorPlace)
11:23AM	7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split (InvestorPlace)
11:01AM	NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial (InvestorPlace)
10:45AM	What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? (Benzinga)
10:39AM	Why Is Verastem (VSTM) Stock Down 62% Today? (InvestorPlace)
08:47AM	ASCO 2024: Verastems combo therapy for pancreatic cancer hits early trial success (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:00AM	Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
May-23-24 05:01PM	Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer? (Business Wire)
May-09-24 10:58PM	VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 (InvestorPlace)
04:56PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
May-07-24 07:30AM	Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48% +7.51%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Jun 20 '25	Sale	5.13	17,808	91,355	443,839	Jun 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '25	Sale	5.13	4,110	21,084	109,945	Jun 24 04:37 PM
Calkins Daniel	Chief Financial Officer	Jun 23 '25	Sale	4.71	25	118	109,920	Jun 24 04:37 PM
Dan Paterson	Officer	Jun 20 '25	Proposed Sale	5.13	17,808	91,334		Jun 20 05:35 PM
Paterson Dan	President and CEO	Jun 16 '25	Sale	5.65	335	1,893	461,647	Jun 20 11:22 AM
Gagnon Robert E.	Director	Jun 16 '25	Sale	5.65	284	1,605	42,242	Jun 20 11:22 AM
Stuglik Brian M	Director	Jun 16 '25	Sale	5.65	594	3,356	102,326	Jun 20 11:21 AM
Calkins Daniel	Chief Financial Officer	May 20 '25	Sale	8.13	11,143	90,593	114,055	May 20 07:54 PM
Paterson Dan	President and CEO	May 20 '25	Sale	8.13	58,677	477,044	461,982	May 20 07:52 PM
Daniel Calkins	Officer	May 20 '25	Proposed Sale	8.10	11,143	90,293		May 20 07:49 PM
Dan Paterson	Officer, Director	May 20 '25	Proposed Sale	8.13	58,677	477,044		May 20 07:48 PM
Paterson Dan	President and CEO	May 05 '25	Sale	7.30	820	5,986	345,659	May 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '25	Sale	6.89	65	448	86,374	Mar 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Mar 24 '25	Sale	7.04	26	183	86,348	Mar 24 04:39 PM
Paterson Dan	President and CEO	Mar 17 '25	Sale	6.95	244	1,696	346,479	Mar 19 04:48 PM
Gagnon Robert E.	Director	Mar 17 '25	Sale	6.95	284	1,974	34,193	Mar 19 04:47 PM
Stuglik Brian M	Director	Mar 17 '25	Sale	6.95	593	4,121	94,587	Mar 19 04:46 PM
Paterson Dan	President and CEO	Feb 04 '25	Sale	5.70	858	4,891	346,723	Feb 05 04:30 PM
Paterson Dan	President and CEO	Jan 13 '25	Sale	5.24	8,568	44,896	347,581	Jan 14 04:30 PM
Dan Paterson	Officer, Director	Jan 13 '25	Proposed Sale	5.24	8,568	44,909		Jan 13 05:03 PM
Calkins Daniel	Chief Financial Officer	Jan 06 '25	Sale	6.94	6	42	47,639	Jan 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '24	Sale	4.34	65	282	47,396	Dec 26 04:30 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '24	Sale	3.91	28	109	47,368	Dec 26 04:30 PM
Gagnon Robert E.	Director	Dec 16 '24	Sale	4.54	285	1,294	34,607	Dec 20 04:32 PM
Gagnon Robert E.	Director	Dec 19 '24	Sale	4.37	130	568	34,477	Dec 20 04:32 PM
Stuglik Brian M	Director	Dec 16 '24	Sale	4.54	595	2,701	95,514	Dec 20 04:31 PM
Stuglik Brian M	Director	Dec 19 '24	Sale	4.37	334	1,460	95,180	Dec 20 04:31 PM
Paterson Dan	President and CEO	Dec 16 '24	Sale	4.54	244	1,108	231,332	Dec 20 04:30 PM
Paterson Dan	President and CEO	Dec 19 '24	Sale	4.37	183	800	231,149	Dec 20 04:30 PM
Paterson Dan	President and CEO	Nov 05 '24	Sale	3.84	812	3,118	231,576	Nov 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Oct 07 '24	Sale	2.86	6	17	47,461	Oct 09 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 20 '24	Sale	2.80	65	182	47,495	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '24	Sale	2.68	28	75	47,467	Sep 24 04:30 PM
Gagnon Robert E.	Director	Sep 19 '24	Sale	2.79	131	365	34,892	Sep 20 06:01 PM
Paterson Dan	President and CEO	Sep 19 '24	Sale	2.79	184	513	232,388	Sep 20 06:01 PM
Stuglik Brian M	Director	Sep 19 '24	Sale	2.79	336	937	96,109	Sep 20 06:00 PM
Gagnon Robert E.	Director	Sep 16 '24	Sale	2.80	287	804	35,023	Sep 18 04:30 PM
Stuglik Brian M	Director	Sep 16 '24	Sale	2.80	600	1,680	96,445	Sep 18 04:30 PM
Paterson Dan	President and CEO	Sep 16 '24	Sale	2.80	246	689	232,572	Sep 18 04:30 PM
Paterson Dan	President and CEO	Aug 05 '24	Sale	2.16	3,245	7,009	232,818	Aug 07 04:18 PM

Open in Screener

FBIO

Fortress Biotech Inc

Jul 14 • 04:00PM ET

1.96

Dollar change +0.07
Percentage change 3.70	%

Healthcare • Biotechnology • USA • NASD

FBIO Fortress Biotech Inc daily Stock Chart

Peers: BMRN FOLD PTGX XENE MGTX TGTX QURE ANAB CRSP EDIT

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.32	Insider Own	28.55%	Shs Outstand	29.55M	Perf Week	2.62%
Market Cap	57.96M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	0.00%	Shs Float	21.13M	Perf Month	-6.67%
Enterprise Value	51.10M	PEG	-	EPS next Q	-0.36	Inst Own	16.61%	Short Float	15.13%	Perf Quarter	39.01%
Income	-50.75M	P/S	1.00	EPS this Y	47.96%	Inst Trans	1.75%	Short Ratio	15.81	Perf Half Y	-5.77%
Sales	57.78M	P/B	2.60	EPS next Y	41.07%	ROA	-24.02%	Short Interest	3.20M	Perf YTD	-3.21%
Book/sh	0.75	P/C	0.63	EPS next 5Y	-	ROE	-181.84%	52W High	2.89 -32.18%	Perf Year	12.00%
Cash/sh	3.09	P/FCF	-	EPS past 3/5Y	39.06% 24.49%	ROIC	-54.89%	52W Low	1.33 47.92%	Perf 3Y	-85.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.71% 9.50%	Gross Margin	58.27%	Volatility	6.67% 6.17%	Perf 5Y	-95.33%
Dividend TTM	-	EV/Sales	0.88	EPS Y/Y TTM	88.12%	Oper. Margin	-167.69%	ATR (14)	0.12	Perf 10Y	-96.32%
Dividend Ex-Date	-	Quick Ratio	1.55	Sales Y/Y TTM	-32.11%	Profit Margin	-87.82%	RSI (14)	56.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.72	EPS Q/Q	53.50%	SMA20	5.55%	Beta	1.76	Target Price	10.00
Payout	-	Debt/Eq	3.34	Sales Q/Q	0.84%	SMA50	6.58%	Rel Volume	0.61	Prev Close	1.89
Employees	101	LT Debt/Eq	3.16	Earnings	May 15 AMC	SMA200	10.90%	Avg Volume	202.18K	Price	1.96
IPO	Nov 17, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.03% 13.07%	Trades		Volume	124,491	Change	3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Resumed	ROTH MKM	Buy	$10
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Jul-14-25 08:50AM	Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors (Zacks)
08:30AM	Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi (GlobeNewswire)
Jul-10-25 09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 08:30AM	Journey Medical to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-20-25 08:30AM	Journey Medical Corporation Announces Emrosi Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference (GlobeNewswire)
08:50AM	Loading…
Jun-19-25 08:50AM	Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock (Zacks)
Jun-09-25 08:30AM	Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV (GlobeNewswire) +6.50%
Jun-03-25 08:50AM	Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
May-30-25 10:47AM	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics (GlobeNewswire)
May-16-25 05:50AM	New Strong Sell Stocks for May 16th (Zacks)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.23%
04:25PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-14-25 05:15PM	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-13-25 05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks) +5.45%
04:15PM	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates (GlobeNewswire)
May-08-25 08:50AM	Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-07-25 04:01PM	Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire)
Apr-01-25 04:01PM	Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer (GlobeNewswire)
Mar-31-25 05:50PM	Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-25 08:30AM	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates (GlobeNewswire) -6.94%
Mar-26-25 07:39PM	Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-25-25 09:04AM	Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-24-25 08:30AM	Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea (GlobeNewswire)
Mar-19-25 04:01PM	Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 (GlobeNewswire)
08:55AM	Loading…
Mar-17-25 08:55AM	Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 08:30AM	Journey Medical Corporation to Participate in the 37th Annual ROTH Conference (GlobeNewswire)
Mar-09-25 10:06PM	Sun Pharma to Acquire Checkpoint Therapeutics (PR Newswire)
Mar-05-25 04:15PM	Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi (DFD-29) to Treat Rosacea (GlobeNewswire)
Mar-04-25 04:01PM	Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida (GlobeNewswire)
Feb-27-25 04:05PM	Mustang Bio Announces Sale of Fixed Assets and Exit of Facility (GlobeNewswire)
Feb-11-25 04:10PM	Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-10-25 08:00AM	Mustang Bio Announces Closing of $8 Million Public Offering (GlobeNewswire)
Feb-06-25 07:00AM	Mustang Bio Announces Pricing of $8 Million Public Offering (GlobeNewswire)
Jan-28-25 08:41AM	Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex (TipRanks)
07:21AM	Fortress doses first subject in Phase II CMV vaccine trial (Clinical Trials Arena)
Jan-27-25 08:30AM	Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT (GlobeNewswire)
Jan-23-25 08:30AM	Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire)
Jan-14-25 08:00AM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire)
Jan-07-25 06:59AM	FDA accepts Sentynls Menkes disease therapy NDA for priority review (Pharmaceutical Technology)
Jan-06-25 08:00AM	Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease (PR Newswire)
08:00AM	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease (GlobeNewswire)
Dec-13-24 06:15PM	Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl) (GlobeNewswire)
Nov-14-24 05:04PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance) -8.92%
04:10PM	Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-12-24 04:30PM	Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
04:01PM	Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Mustang Bio Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Nov-07-24 08:30AM	Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma (GlobeNewswire)
Nov-04-24 07:00AM	Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea (GlobeNewswire) -8.95%
Oct-25-24 01:02PM	Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares (GuruFocus.com) +6.94%
08:30AM	Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-24-24 02:10PM	Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds (GlobeNewswire)
Oct-09-24 08:30AM	Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-03-24 08:30AM	Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 08:30AM	Fortress Biotech to Participate in October 2024 Investor Conferences (GlobeNewswire)
Sep-20-24 08:30AM	Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements (GlobeNewswire) -18.75%
Sep-16-24 07:30AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 (GlobeNewswire)
Sep-09-24 08:30AM	Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference (GlobeNewswire)
Sep-04-24 08:30AM	Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.08%
08:15AM	Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
08:00AM	Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 08:30AM	Avenue Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 08:50AM	Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Aug-13-24 05:15PM	Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:16PM	Fortress Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Aug-09-24 04:05PM	Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-06-24 04:01PM	Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024 (GlobeNewswire)
Jul-25-24 08:30AM	Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 (GlobeNewswire) +5.69%
07:30AM	Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-15-24 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO) (Zacks)
08:00AM	GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research (GlobeNewswire)
Jul-11-24 04:05PM	Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors (GlobeNewswire) +12.57%
Jul-05-24 04:05PM	Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (GlobeNewswire)
Jul-02-24 08:00AM	Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab (GlobeNewswire)
Jun-24-24 07:30AM	Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission (GlobeNewswire)
Jun-21-24 04:01PM	Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-20-24 08:30AM	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
08:00AM	Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jun-17-24 08:30AM	Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy (GlobeNewswire)
May-16-24 08:30AM	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
May-15-24 10:53PM	FBIO Stock Earnings: Fortress Biotech Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:32PM	Fortress Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase (GlobeNewswire)
08:30AM	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-14-24 11:14AM	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex (MT Newswires)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fortress Biotech, Inc.	10% Owner	May 29 '25	Sale	1.29	100,000	129,000	6,122,249	Jun 03 06:34 PM
ROSENWALD LINDSAY A MD	PRESIDENT, CEO & CHAIRMAN	Sep 23 '24	Buy	1.84	763,359	1,404,581	3,657,264	Sep 25 04:45 PM

BIIB

Biogen Inc

VSTM

Verastem Inc

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience